Tromsø, Norway, May 7, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported first-quarter 2026 results, with sales up 36% year-on-year to NOK 31.8 million and positive EBITDA — a NOK 5.3 million turnaround versus Q1 2025. Growth was broad-based across both business segments, with Molecular Tools rebounding sharply and Biomanufacturing extending its commercial reach among global CDMOs.
Q1 2026 Highlights
- Total Revenue: NOK 35 million (Q1 2025: NOK24.9 million), +41% YoY
- Sales Revenue: NOK 31.8 million (Q1 2025: NOK 23.3 million), +36% YoY
- At constant exchange rates (CER): NOK 35 million, +50% YoY
- EBITDA: NOK 1.6 million (Q1 2025: NOK -3.7 million)
- EBITDA turnaround of NOK 5.3 million YoY
- EBITDA margin: 5% (Q1 2025: negative)
Biomanufacturing — NOK 15.1m (+11% YoY)
M-SAN HQ drove growth, recording its second-best quarter on record for both the nuclease product and the companion ELISA kit. The product continued to win recurring business with top-tier global CDMOs, where its performance in viral vector manufacturing is generating both new customer acquisition and repeat orders. Geographic breadth was a feature of the quarter, with growth across multiple regions. In North America, a handful of larger orders on the US East Coast shifted into the second half; this is expected to be timing-related and is reflected in the Company's full-year planning.
Molecular Tools — NOK 16.6m (+72% YoY)
The segment returned to strong growth, recovering from a prior-year quarter affected by customer order timing. Recurring OEM relationships - with order visibility extending through 2026 - anchored the result, while direct accounts across research and diagnostic applications contributed healthy incremental growth. The commercial momentum established in Q1 within Molecular tools is expected to be sustained through the year.
Leading Products
The five highest-contributing product groups in Q1 were M-SAN HQ, dsDNases, Cod UNG, SAN HQ, and rSAP + ExoI — a lineup that reflects the breadth of ArcticZymes' enzyme platform across nuclease, decontamination, and sample preparation workflows.
CEO Commentary
"The Q1 result demonstrates that our commercial engine is gaining traction in the right places," said Michael Akoh, CEO of ArcticZymes Technologies ASA. "M-SAN is becoming an
important component in viral vector manufacturing at leading CDMOs, and the recovery in Molecular Tools reflects recurring relationships that give us real revenue visibility within the segment. We enter the rest of 2026 with confidence in our team’s ability to execute on the strategy we presented at our CMD in March."
Outlook
ArcticZymes enters the remainder of 2026 with revenue momentum, and growing commercial reach across both segments. The Company's priorities for 2026 remain consistent with those outlined at the March Capital Markets Day: deepening Salt Active Nuclease penetration in Biomanufacturing, expanding into molecular diagnostics and advanced therapy workflows, and advancing RNA enzyme and metagenomics capabilities. With recurring OEM order visibility, a differentiated enzyme portfolio, and a robust balance sheet, the Company is focused on converting commercial momentum into sustained, profitable growth.
Presentation and Webcast
The Company will host a virtual Q1 2026 presentation for investors, analysts and media at 8:30 CET on Thursday, May 7, 2026.
The presentation will be given by CEO, Michael Akoh, CFO, Børge Sørvoll and CCO Paul Blackburn.
The presentation can be followed as a live webcast from Hegnar TV on https://qcnl.tv/p/XRgPIoZrlRfhnjAmevVbeQ or www.arcticzymes.com. It will be possible to post questions through the webcast console.
The report for Q1 2026 will be available on www.newsweb.no and on the company's homepage www.arcticzymes.com from 07.00 CET on May 7, 2026.
For more information, please contact:
ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com
